These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. UK HARP-III Collaborative Group Nephrol Dial Transplant; 2017 Dec; 32(12):2043-2051. PubMed ID: 27646835 [TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application. Kuang H; Huang X; Zhou Z; Cheng X; Xu G Eur J Pharmacol; 2021 Sep; 907():174288. PubMed ID: 34216577 [TBL] [Abstract][Full Text] [Related]
7. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551 [TBL] [Abstract][Full Text] [Related]
8. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis. Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574 [TBL] [Abstract][Full Text] [Related]
11. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829 [TBL] [Abstract][Full Text] [Related]
12. [Angiotensin-neprilysin inhibition in ckd: does it confer a double benefit?]. Wojtaszek E Wiad Lek; 2019; 72(11 cz 2):2228-2231. PubMed ID: 31860842 [TBL] [Abstract][Full Text] [Related]
13. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? Malek V; Gaikwad AB Biomed Pharmacother; 2017 Jun; 90():752-759. PubMed ID: 28419972 [TBL] [Abstract][Full Text] [Related]
14. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan. Liu RC Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980 [TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. Perrone-Filardi P; Paolillo S; Agostoni P; Basile C; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Indolfi C; Sinagra G Eur J Intern Med; 2022 Aug; 102():8-16. PubMed ID: 35469709 [TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. von Lueder TG; Sangaralingham SJ; Wang BH; Kompa AR; Atar D; Burnett JC; Krum H Circ Heart Fail; 2013 May; 6(3):594-605. PubMed ID: 23694773 [No Abstract] [Full Text] [Related]
17. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Díez J Eur J Heart Fail; 2017 Feb; 19(2):167-176. PubMed ID: 27766748 [TBL] [Abstract][Full Text] [Related]